HOM 2 secunda

Glavne informacije

  • Zaščiteno ime:
  • HOM 2 secunda
  • Farmacevtska oblika:
  • prašek za peroralno raztopino
  • Pot uporabe:
  • Peroralna uporaba
  • Enote v paketu:
  • pločevinka s 500 g praška
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Alopatska drog

Dokumentov

Lokalizacija

  • Na voljo v:
  • HOM 2 secunda
    Slovenija
  • Jezik:
  • slovenščina

Terapevtski podatki

  • Terapevtska skupina:
  • Hranila za otroke

Drugi podatki

Stanje

  • Source:
  • JAZMP - Javna agencija RS za zdravila in medicinske pripomočke - Slovenia Medicines Agency
  • Status dovoljenje:
  • Živilo
  • Zadnja posodobitev:
  • 18-01-2018

Podatki za bolnike

MILUPA HOM 2 secunda

Dietno (dietetično) živilo za posebne zdravstvene namene.

Izdelek HOM 2 secunda je namenjen za dietetsko uravnavanje homocistinurije pri otrocih nad 8. letom

starosti in mladostnikih.

POMEMBNO OPOZORILO:

Izdelek se uporablja izključno pod zdravniškim nadzorom!

Izdelek ni primeren kot edini vir prehrane.

Izdelek ni primeren za parenteralno uporabo!

Upoštevajte navodila za uporabo!

Izdelek je primeren izključno za bolnike s homocistinurijo.

INDIKACIJE:

Milupa HOM 2 secunda je mešanica čistih L-aminokislin, ne vsebuje metionina in je obogatena z L-cistinom, vitamini,

minerali

elementi

sledovih. HOM

2 secunda

uporablja

beljakovinski dodatek

za dietetsko

uravnavanje

homocistinurije pri otrocih nad 8. letom starosti in mladostnikih.

DOZIRANJE:

Skupna količina HOM 2 secunda, potrebna za pokritje dnevnih potreb po beljakovinah (razen metionina), je odvisna od

starosti, telesne teže in individualne tolerance metionina. Ustrezni odmerek HOM 2 secunda določi oz. predpiše zdravnik v

določenih časovnih presledkih.

UPORABA:

Predpisano dnevno količino HOM 2 secunda razdelimo na 3 do 5 posameznih obrokov ter pomešamo s preračunano količino

ostale hrane (npr.: napitki, sadne kreme, kaše). Dieta s HOM 2 secunda mora za zagotovitev dnevnih potreb vsebovati

ustrezno količino energije, bistvene maščobne kisline in metionin.

Sestava/ tipična

analiza HOM 2 secunda

v

100 g

v

100 g

100g vsebuje:

Energija

1240 kJ / 292 kcal

Beljakovine*

g

70

Aminokisline

g

84

Arginin g 2,7

Cistin g 3,4

Histidin g 1,8

Isoleucin g 4,6

Levcin g 7,8

Lisin g 5,5

Fenilalanin g 3,3

Treonin g 3,6

Triptofan g 1,4

Tirozin g 4

Valin g 5,5

Alanin g 3,2

Asparaginska kislina g 7,8

Glutaminska kislina g 16,3

Glicin g 1,8

Prolin g 7,2

Serin g 4,1

Karnitin mg 150

Maščobe

g

0

Od tega nasičene g 0

Oglj. hidrati

g

2,9

Od tega sladkorji g 0,1

Vlaknine g

0

Vitamini

Vitamin A

Vitamin D

Vitamin E

Vitamin K

Vitamin B

Vitamin B

Vitamin B

Niacin

Biotin

Folat

Vitamin B

Pantotenska kislina

Vitamin C

Holin

Mio-inositol

Minerali

Natrij mg

Kalij mg

Kalcij mg

Magnezij mg

Fosfor mg

Klorid mg

Železo mg

1070

13,1

< 3

1400

1680

<1

Elementi v sledovih

Cink mg

Baker μg

Jod μg

Mangan mg

Krom μg

Fluor mg

Molibden μg

Selen μg

*Preračunano:

1g beljakovin =

1,2g aminokislin

= 17kJ = 4 kcal

1400

Sestavine:

L-lizin-L-glutamat, L-glutaminska kislina, L-levcin, L-prolin, L-valin, magnezijev-L-aspartat, L-izoleucin, L-

serin, L-tirozin, L-aspartamska kislina, L-treonin, L-cistin, L-fenilalanin, L-alanin, kalijev orto fosfat, maltodekstrin, kalcijev

karbonat, L-arginin, kalcijev ortofosfat, glicin, L-histidin, holin bitartrat, L-triptofan, inozitol, L-karnitin, L-askorbinska

kislina, železov sulfat, cinkov sulfat, vanilin, DL-alfa-tokoferil acetat, niacinamid, kalcijev-D-pantotenat, manganov sulfat,

bakrov sulfat, piridoksin hidroklorid, natrijev florid, tiamin mononitrat, riboflavin, retinil acetat, pteroil monoglutaminska

kislina,

kalijev

jodid,

kromov

klorid,

natrijev

selenit,

amonijev

molibdat,

D-biotin,

filokinon,

holekalciferol,

cianokobalamin.

Prosimo, pazite na zobno nego vašega otroka, posebno pred spanjem.

Pločevinko hranimo tesno zaprto v hladnem in suhem prostoru. Po odprtju embalaže moramo vsebino porabiti v 4

tednih.

Pakiranje:

pločevinka 500 g

Pakirano v kontrolirani atmosferi.

Uporabno najmanj do:

Rok uporabe in serija sta odtisnjena na dnu pločevinke.

Nosilec živilske dejavnosti:

Milupa GmbH & Co. KG, 61381 Friedrichsdorf, Nemčija

Zastopnik in distributer:

KEFo d.o.o., Brnčičeva 29, 1231 Ljubljana-Črnuče

16-11-2018

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot

The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.

FDA - U.S. Food and Drug Administration

23-10-2018

October 22, 2018: Oklahoma Orthopedic Company to Pay $455,000 to Settle Claims of False Medical Billing

October 22, 2018: Oklahoma Orthopedic Company to Pay $455,000 to Settle Claims of False Medical Billing

October 22, 2018: Oklahoma Orthopedic Company to Pay $455,000 to Settle Claims of False Medical Billing

FDA - U.S. Food and Drug Administration

17-10-2018

Pest categorisation of Stagonosporopsis andigena

Pest categorisation of Stagonosporopsis andigena

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The Panel on Plant Health performed a pest categorisation of Stagonosporopsis andigena, the causal agent of black blight of potato, for the EU. The pest is a well‐defined fungal species and reliable methods exist for its detection and identification. S. andigena is present in Bolivia and Peru. The pest is not known to occur in the EU and is listed in Annex IAI of Directive 2000/29/EC as Phoma andina, meaning its introduction into the EU is prohibited. The ma...

Europe - EFSA - European Food Safety Authority Publications

30-8-2018

District Court orders permanent injunction against companies selling sexual enhancement products containing undisclosed drugs

District Court orders permanent injunction against companies selling sexual enhancement products containing undisclosed drugs

The U.S. District Court for the District of New Jersey entered an order of permanent injunction against S Hackett Marketing LLC doing business as Just Enhance; R Thomas Marketing LLC; Shawn Hackett, president and owner of Just Enhance; and Roger Thomas, president and founder of R Thomas Marketing LLC. The permanent injunction requires the defendants to, among other things, cease the distribution of drugs until they take specific remedial measures and comply with the Federal Food, Drug, and Cosmetic Act (...

FDA - U.S. Food and Drug Administration

8-8-2018

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy

FDA - U.S. Food and Drug Administration

2-8-2018

Orphan designation:  Lenalidomide,  for the: Treatment of diffuse large B-cell lymphoma

Orphan designation: Lenalidomide, for the: Treatment of diffuse large B-cell lymphoma

On 13 May 2011, orphan designation (EU/3/11/868) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for lenalidomide for the treatment of diffuse large B-cell lymphoma.

Europe - EMA - European Medicines Agency

2-8-2018

Orphan designation:  Lenalidomide,  for the: Treatment of follicular lymphoma

Orphan designation: Lenalidomide, for the: Treatment of follicular lymphoma

Europe - EMA - European Medicines Agency

29-5-2018

Orphan designation:  Venetoclax,  for the: Treatment of mantle cell lymphoma

Orphan designation: Venetoclax, for the: Treatment of mantle cell lymphoma

Europe - EMA - European Medicines Agency

15-5-2018

Orphan designation:  Tazemetostat,  for the: Treatment of follicular lymphoma

Orphan designation: Tazemetostat, for the: Treatment of follicular lymphoma

Europe - EMA - European Medicines Agency

9-5-2018

Breast implants and anaplastic large cell lymphoma

Breast implants and anaplastic large cell lymphoma

Update on number of confirmed BIA-ALCL cases in Australia

Therapeutic Goods Administration - Australia

2-3-2018

European top post for Thomas Senderovitz

European top post for Thomas Senderovitz

Director General of the Danish Medicines Agency, Thomas Senderovitz, was Thursday elected Chairperson of the HMA Management Group. HMA is an acronym for Heads of Medicines Agencies and is the network of the heads of the national drug regulatory authorities in Europe.

Danish Medicines Agency

15-4-2016

Promising prospects for cooperation with Mexico

Promising prospects for cooperation with Mexico

Thursday, the Danish Medicines Agency's new Director General Thomas Senderovitz signed a cooperation agreement between the Mexican drug regulatory authority and the Danish Medicines Agency.

Danish Medicines Agency

11-1-2016

New  Director General of the Danish Medicines Agency

New Director General of the Danish Medicines Agency

The Danish Ministry of Health has appointed Thomas Senderovitz as Director General of the newly established Danish Medicines Agency.

Danish Medicines Agency

4-6-2018

EU/3/05/334 (Florence Porte ThomE)

EU/3/05/334 (Florence Porte ThomE)

EU/3/05/334 (Active substance: Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein) - Transfer of orphan designation - Commission Decision (2018)3629 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/064/05/T/03

Europe -DG Health and Food Safety